-
Maternal serum inhibin-A and free beta-hCG concentrations in trisomy 21 pregnancies at 10-14 weeks of gestation.
Noble PL, Wallace EM, Snijders RJ, Groome NP, Nicolaides KH.
BJOG 1997;104:367-71. -
Down's syndrome screening with nuchal translucency.
Nicolaides KH, Sebire NJ, Snijders RJ.
Lancet 1997;349:438. -
Screening for trisomy 21 in twin pregnancies by maternal age and fetal nuchal translucency thickness at 10-14 weeks of gestation.
Sebire NJ, Snijders RJM, Hughes K, Sepulveda W, Nicolaides KH.
BJOG 1996;103:999-1003. -
Down's syndrome screeening in the UK.
Nicolaides KH, Sebire NJ, Snijders RJ, Johnson S, Reynolds TM.
Lancet 1996;347:906-7. -
Intrauterine lethality of trisomy 21 fetuses with increased nuchal translucency.
Hyett JH, Sebire NJ, Snijders RJM, Nicolaides KH.
Ultrasound Obstet Gynecol 1996;7:101-3. -
Natural history of trisomy 21 Fetuses with fetal nuchal translucency.
Pandya PP, Snijders RJM, Johnson S, Nicolaides KH.
Ultrasound Obstet Gynecol 1995;5:381-3. -
Screening for fetal trisomy 21 in the first trimester of pregnancy: maternal serum free beta-hCG and fetal nuchal translucency thickness.
Noble PL, Abraha HD, Snijders RJ, Sherwood R, Nicolaides KH.
Ultrasound Obstet Gynecol 1995;6:390-5. -
First trimester nuchal translucency and cardiac septal defects in fetuses with trisomy 21.
Hyett JA, Moscoso G, Nicolaides KH.
Am J Obstet Gynecol 1995;172:1411-3. -
Increased nuchal translucency in Trisomy 21 fetuses: Relation to narrowing of the aortic isthmus.
Hyett JA, Moscoso G, Nicolaides KH.
Hum Reprod 1995;10:3049-3051.